LUCERNE, Switzerland, Jan. 21, 2025 (Korea Bizwire) – Neoviva, a leading luxury rehab centre launches Switzerland’s first and only assurance programme in addiction treatment. With a structured and tailored approach, Neoviva’s programme addresses the unique needs of each client, blending cutting-edge therapeutic methods with comprehensive aftercare. The Neoviva Guarantee is a testament to the effectiveness [...]
Ad hoc announcement under Art. 53 LR Baar (Switzerland), 21 January 2025 Based on preliminary unaudited figures, Ascom reports for fiscal year 2024 a revenue of CHF 286.7 million, which is a decline of 1.6% at constant currencies, and an EBITDA margin of around 7.5%. In a continuing challenging market environment, Ascom generated net revenue [...]
SHANGHAI, Jan. 20, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced a distribution and marketing partnership with LEO Pharma for toripalimab in Europe. [...]
SHANGHAI, Jan. 17, 2025 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announced that toripalimab, the anti-PD-1 monoclonal antibody self-developed by the company, has obtained [...]
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically significant effects on cognition or functioning were observed in patients treated with iclepertin versus placebo at six months.1 All three trials demonstrated that iclepertin, a [...]
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally – have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratings for both to favorable* after assessing the most [...]
Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025 Ambitious GLP-1 strategy in [...]
WAKE FOREST, N.C. and ADELAIDE, Australia, Jan. 13, 2025 (Korea Bizwire) – Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce it is the CRO of choice for early phase clinical trials in Australia with more than 52% of market share. Avance Clinical [...]
Rochester, N.Y., Jan. 13, 2025 (Korea Bizwire) – Carestream Health, a leading provider of medical imaging solutions, announced today the addition of new features to its popular DRX-Revolution Mobile X-ray System. These new features continue Carestream’s tradition of innovative, mobile imaging excellence to help improve efficiency, ease of use, and image quality. The DRX-Revolution Mobile [...]
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon’s biosimilar candidate to Eylea®1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon’s biosimilar to Lucentis®2 (ranibizumab) in Europe The partnership broadens Teva’s biosimilars portfolio, in line with its Pivot to Growth strategy TEL AVIV, Israel, Jan. 13, 2025 [...]